The Motley Fool

Should I buy FTSE 100 shares Lloyds, Tesco, or Glaxo in July?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Scene depicting the City of London, home of the FTSE 100
Image source: Getty Images.

I’m hunting for top FTSE 100 shares to buy this July. Which of these British blue chip stocks should I pick up?

Tesco’s travails

The Tesco (LSE: TSCO) share price got off to a flyer in June before falling sharply following the release of fresh financials. I’m not taking the opportunity to buy in on the dip though given the increasingly competitive pressures it faces.

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story. In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

The FTSE 100 firm still sits at the top of the UK grocery market. But its crown has lost much of its lustre thanks to the growth of the low-cost and premium supermarkets. And the chances of Tesco returning to steamroll the competition are dwindling as its competitors expand their operations on the high street and on the Internet. Discounter Lidl remains on course to open 140 stores in Britain by 2023, it said this week.

Okay, Tesco still has plenty of clout and it is investing heavily to improve its operations in the fast-growing online channel. However, I still worry that the company will struggle to generate decent profits growth as worsening competition shreds its margins.

Lloyds under pressure

I’m also not surprised that the Lloyds Banking Group (LSE: LLOY) share price has struggled in June. It’s just the threat posed by a spike in Covid-19 cases and the repercussions for the domestic economy. Arguably the possibility of rock-bottom interest rates lasting long into the future creates an even bigger risk to the FTSE 100 bank’s profits.

The Bank of England this week raised its inflation forecast to 3% from 2.5% previously. This is even further ahead of the institution’s 2% target. But policymakers said that they are determined to keep interest rates locked around current lows of 0.1%, describing the recent surge in prices as “transitory.”

This creates problems for Lloyds as it narrows the difference banks can charge people to borrow and what it can give savers. And I don’t expect interest rates to rise considerably any time soon as the UK economy battles economic hangovers from Covid-19 and Brexit. It’s true that the robust housing market could drive profits higher at the bank (Lloyds is by far Britain’s biggest mortgage lender). But I still think the risks of buying Lloyds shares far outweigh the potential rewards.

I’d rather buy this FTSE 100 share

While I’ll be giving Tesco and Lloyds a miss this July, I’m looking at buying GlaxoSmithKline (LSE: GSK) for my shares portfolio. This UK healthcare share has performed better price-wise than those other FTSE 100 stocks so far this month. But this momentum moving into the summer isn’t the reason I’d buy it today.

I always buy stocks according to what returns I can expect to make over the long term (ideally a decade or more). And I think Glaxo will thrive as global healthcare investment goes from strength to strength. The firm has a packed drugs pipeline in key therapy areas like infectious diseases, HIV, and oncology. What’s more, the business has described many of its 20 vaccines and 42 medicines as “potential best or first in class opportunities.”

The business of drugs development can be highly unpredictable. And setbacks can have huge financial implications for pharma companies like this. That said, Glaxo has a great track record on this front and so I’d happily buy it in July.

I also think the FTSE 100 stock discussed in this special The Motley Fool report is a top stock to buy next month.

There’s a ‘double agent’ hiding in the FTSE… we recommend you buy it!

Don’t miss our special stock presentation.

It contains details of a UK-listed company our Motley Fool UK analysts are extremely enthusiastic about.

They think it’s offering an incredible opportunity to grow your wealth over the long term – at its current price – regardless of what happens in the wider market.

That’s why they’re referring to it as the FTSE’s ‘double agent’.

Because they believe it’s working both with the market… And against it.

To find out why we think you should add it to your portfolio today…

Click here to get access to our presentation, and learn how to get the name of this 'double agent'!

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline, Lloyds Banking Group, and Tesco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.